Analysts at Roth Capital upgrade Actuate Corporation ACTU from "hold" to "buy." The target price for ACTU is set to $5.50.
ACTU's shares gained 2.35% to close at $4.36 on Friday.
More Analyst Ratings here
ACTUActuate Therapeutics Inc
$7.440.54%
Edge Rankings
Momentum-
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
